Hospital for Special Surgery, New York

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Hospital for Special Surgery, New York sits in the top decile of US sponsors by registered trial count (#155 of 15,742 sponsors by registered trial count).

194 total trials 35 currently recruiting 123 completed later-stage tilt top decile by trial count

Hospital for Special Surgery, New York: 194 sponsored US clinical trials, 35 recruiting.

Hospital for Special Surgery, New York sponsors 194 registered US clinical trials on ClinicalTrials.gov, 35 of them currently recruiting, and 123 completed. 58 of these trials are in Phase 3-4 (later-stage) and 19 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Opioid Use, with 7 trials.

Top-decile sponsor footprint

Hospital for Special Surgery, New York ranks in the top decile of sponsors by registered trial count (#155 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 52/100

123 of 145 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

194 total, page 4 of 4

COMPLETED Phase 2

Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis

NCT01670565

COMPLETED NA

Effect of Local Anesthetic Dose on Interscalene Block

NCT01701115

COMPLETED Phase 4

Comparing Subsartorial Saphenous Nerve Blocks With and Without Dexamethasone for Anterior Cruciate Ligament Reconstruction

NCT01586806

COMPLETED NA

Saphenous Nerve Block vs. Femoral Nerve Block for Total Knee Arthroplasty

NCT01505374

COMPLETED NA

Study of Melatonin on Sleep, Pain, and Confusion After Joint Replacement Surgery

NCT01505465

COMPLETED NA

Analgesia After Total Hip Arthroplasty: Peri-Articular Injection Versus Epidural Patient Controlled Analgesia (PCA)

NCT01658072

COMPLETED

Interscalene Dynamometer Pilot Study

NCT01550952

COMPLETED NA

Study to Find Optimal Dose of Local Spinal Anesthetic (Mepivacaine) Combined With Narcotic (Fentanyl) For Knee Surgery

NCT01701102

COMPLETED NA

Doppler Ultrasound Following Unicondylar Knee Replacement to Determine the Incidence of Postoperative DVT

NCT02148757

COMPLETED Phase 1

Effects of Pregabalin on Pain After Total Knee Arthroplasty

NCT01333956

COMPLETED Phase 2

Study of Tocilizumab to Treat Polymyalgia Rheumatica

NCT01396317

COMPLETED NA

Ischemic Preconditioning in Total Knee Arthroplasty

NCT01333969

COMPLETED Phase 4

MRI Results in Dupuytren's Contracture Before and After Injection With Xiaflex

NCT01450397

COMPLETED NA

Saphenous Nerve Block Versus Femoral Nerve Block for Total Knee Arthroplasty

NCT01333943

COMPLETED Phase 4

Effect of Low Dose Corticosteroids on Perioperative Markers of Thrombosis and Fibrinolysis in Total Knee Arthroplasty

NCT01815918

COMPLETED NA

A Prospective Randomized Study on the Clinical Benefits of OrthoPAT Drains

NCT02286102

COMPLETED NA

Conventional Alignment System Versus Surgical Navigation System in Total Knee Arthroplasty

NCT01797731

COMPLETED NA

Duration of Analgesia After Popliteal Fossa Nerve Blockade: Effects of Dexamethasone and Buprenorphine

NCT01277159

COMPLETED

Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE)

NCT01475149

COMPLETED Phase 4

The Use of Evicel to Reduce Blood Loss in Total Knee Replacement Surgery

NCT01235715

COMPLETED Phase 2

Nilotinib in the Treatment of Systemic Sclerosis

NCT01166139

COMPLETED Phase 4

Lumbar Plexus Block for Postoperative Pain Control After Hip Arthroscopy. A Randomized Controlled Trial

NCT01286805

COMPLETED

Vitamin D and Functional Outcomes After Total Hip Arthroplasty (THA)

NCT01397383

COMPLETED Phase 4

Analgesia After Total Knee Arthroplasty: Peri-Articular Injection Versus Epidural + Femoral Nerve Blockade

NCT01335542

COMPLETED Phase 4

Antiemetic Prophylaxis for Postdischarge Nausea and Vomiting After Hip Arthroscopy

NCT00878228

COMPLETED Phase 4

Steroids in Bilateral Total Knee Replacement

NCT01399268

COMPLETED NA

Pregabalin for the Treatment of Pain After Posterior Spinal Fusions

NCT01366196

COMPLETED Phase 2

Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients

NCT00674297

COMPLETED Phase 4

The Use of FLOSEAL to Reduce Bleeding in Total Knee Replacement Surgery

NCT00990288

COMPLETED Phase 2

A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome

NCT00537290

COMPLETED Phase 2

Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis

NCT00555581

COMPLETED Phase 3

A Study of Hyaluronan for the Treatment of Osteoarthritis in the Thumb

NCT00398866

COMPLETED Phase 4

Unipedicular vs. Bipedicular Kyphoplasty for the Treatment of Osteoporotic Vertebral Fractures

NCT01383616

TERMINATED Phase 3

Prospective Assessment of the Efficacy of Hyaluronate Knee Injections in Patients With Osteoarthritis

NCT00323778

TERMINATED NA

Memory and Attention Problems in Lupus: New Treatment Trial With Modafinil

NCT00297284

COMPLETED NA

A Pre-Operative Screening Questionnaire (AMS-Q) for Ambulatory Orthopedic Surgery Patients

NCT00337584

COMPLETED NA

Asthma Patient Education in the Emergency Room

NCT00110409

COMPLETED NA

An Open Label Trial for Treating Carpometacarpal Osteoarthritis of the Thumb: Pilot Study

NCT00198029

COMPLETED NA

Bone Tunnel Widening Following ACL Reconstruction

NCT00198042

COMPLETED

Expectations, Satisfaction and Quality of Life in Total Hip Arthroplasty

NCT00197990

COMPLETED NA

Addressing Patients' Expectations of Total Hip Arthroplasty in a Randomized Trial

NCT00198003

COMPLETED NA

Addressing Patients' Expectations of Total Knee Arthroplasty in a Randomized Trial

NCT00197977

COMPLETED NA

A Randomized Trial to Improve Quality of Life Outcomes in Asthma Patients

NCT00197964

COMPLETED

Job Adaptation in Patients With Rheumatoid Arthritis

NCT00412399

← Previous Page 4 of 4

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 14
Phase 3 8
Phase 4 50

Where Hospital for Special Surgery, New York enrollment is open (later-stage tilt)

35 recruiting of 194 indexed (18% open); 123 completed (63%).

Phase mix: 58 late (III/IV) vs 19 early (I/II) (later-stage heavy).

Top condition: Opioid Use (7 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Hospital for Special Surgery, New York: open-pipeline peers nationwide

Peers matched on 194 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

Hospital for Special Surgery, New York sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300400500 0%5%10%15%20% Total trials Recruiting share Hospital for Special Surgery, New YorkGenzyme, a Sanofi CompanyVertex Pharmaceuticals IncorporatedVanderbilt-Ingram Cancer CenterNationwide Children's HospitalGeorge Washington UniversityWest Virginia UniversityUniversity of California, BerkeleyChildren's Hospital of Philadelphia
Hospital for Special Surgery, New York sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Hospital for Special Surgery, New York sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 194 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

What to do with this Hospital for Special Surgery, New York page

194 registered trials is a research-attention snapshot, not an endorsement of Hospital for Special Surgery, New York or any single study.

  • 35 of Hospital for Special Surgery, New York's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Opioid Use is the condition Hospital for Special Surgery, New York studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Opioid Use trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Hospital for Special Surgery, New York pipeline card: 194 registered trials from official public datasets.Report a data error.